Clinical Research Studies

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

• Conditions:
  Cutaneous Lupus Erythematosus
• Age: Between 18 Year(s) - 75 Year(s)
• Gender: Male or Female

• Other Inclusion Criteria:
  

  SP1 inclusion criteria:
  1. Willing to provide informed consent for research skin biopsies and provide clinical information, photographs of skin lesions and biospecimens.
  2. Meet Gilliam classification criteria for acute CLE (ACLE), subacute CLE (SCLE) and certain chronic CLE (CCLE).
  3. Routine histologic evidence (within 10 years) of CLE.
  4. Any degree of CLE activity/severity.

  SP2 inclusion criteria:
  1. Willing to provide informed consent for research skin biopsies and provide clinical information, photographs of skin lesions and biospecimens.
  2. Meet Gilliam classification criteria for SCLE and certain CCLE.
  3. Routine histologic evidence (within 10 years) of CLE.
  4. Disease activity requiring initiation or escalation of systemic therapy to evaluate changes in transcriptomics and proteomics between responders and non-responders.

  
  

You may not be eligible for this study if the following are true:

• 1. Not able to understand the informed consent.
  2. Drug-induced SCLE.
  3. Participants with lupus panniculitis or bullous LE.
  4. Receiving prednisone >5mg/day or the equivalent.
  5. Patient is currently on or has taken within the last 6 months cyclophosphamide, rituximab, retinoids, MMF, methotrexate, azathioprine, biologics (e.g., belimumab, anifrolumab), systemic calcineurin inhibitors, thalidomide, lenalidomide, dapsone, and/or prednisone >5mg or the equivalent
  6. Use of topical medications on lesions to be biopsied during two weeks prior to skin biopsy.
  7. Participants with a history of keloidal scarring or bleeding tendencies.